MARKET

ABOS

ABOS

Acumen Pharmaceuticals, Inc.
NASDAQ
1.260
+0.040
+3.28%
After Hours: 1.260 0 0.00% 16:23 03/14 EDT
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.280
LOW
1.210
VOLUME
154.99K
TURNOVER
--
52 WEEK HIGH
4.490
52 WEEK LOW
1.100
MARKET CAP
75.70M
P/E (TTM)
-0.9195
1D
5D
1M
3M
1Y
5Y
1D
Acumen Pharmaceuticals Announces Upcoming Scientific Presentations On Alzheimer's Therapeutics At AD/PD In Vienna And AAN Annual Meeting In San Diego April 2025
Benzinga · 4d ago
Weekly Report: what happened at ABOS last week (0303-0307)?
Weekly Report · 6d ago
Weekly Report: what happened at ABOS last week (0224-0228)?
Weekly Report · 03/03 09:08
Weekly Report: what happened at ABOS last week (0217-0221)?
Weekly Report · 02/24 09:08
Weekly Report: what happened at ABOS last week (0210-0214)?
Weekly Report · 02/17 09:08
Weekly Report: what happened at ABOS last week (0203-0207)?
Weekly Report · 02/10 09:08
Weekly Report: what happened at ABOS last week (0127-0131)?
Weekly Report · 02/03 09:08
Weekly Report: what happened at ABOS last week (0120-0124)?
Weekly Report · 01/27 09:08
More
About ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.

Webull offers Acumen Pharmaceuticals Inc stock information, including NASDAQ: ABOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABOS stock methods without spending real money on the virtual paper trading platform.